Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 1 of 1 for:    NCT01174199
Previous Study | Return to List | Next Study

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

This study has been terminated.
(no value in finding efficacy)
Sponsor:
Collaborators:
Merck Sharp & Dohme Corp.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Roswell Park Cancer Institute
ClinicalTrials.gov Identifier:
NCT01174199
First received: July 30, 2010
Last updated: September 9, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: August 2016
  Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)